Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($6.06) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) EPS for the quarter, missing the consensus estimate of ($5.26) by ($0.42). During the same period last year, the business earned ($4.98) earnings per share. On average, analysts expect Madrigal Pharmaceuticals to post $-22 EPS for the current fiscal year and $-14 EPS for the next fiscal year.
Madrigal Pharmaceuticals Stock Up 6.4 %
Shares of Madrigal Pharmaceuticals stock opened at $229.84 on Monday. The stock has a 50-day moving average price of $240.99 and a 200 day moving average price of $215.73. Madrigal Pharmaceuticals has a 1 year low of $119.76 and a 1 year high of $313.11. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.38 and a quick ratio of 5.38.
Insider Activity at Madrigal Pharmaceuticals
Analyst Ratings Changes
MDGL has been the subject of several recent research reports. StockNews.com upgraded Madrigal Pharmaceuticals to a “sell” rating in a report on Friday, April 12th. Canaccord Genuity Group upped their price target on Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. JMP Securities raised their price objective on Madrigal Pharmaceuticals from $351.00 to $397.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. Citigroup raised their price objective on Madrigal Pharmaceuticals from $382.00 to $389.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Finally, Piper Sandler reissued an “overweight” rating and issued a $336.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Thursday, March 14th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $356.73.
Get Our Latest Analysis on MDGL
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Read More
- Five stocks we like better than Madrigal Pharmaceuticals
- ETF Screener: Uses and Step-by-Step Guide
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- How Can Investors Benefit From After-Hours Trading
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.